NCT06557785View on ClinicalTrials.gov

A Clinical Trial to Evaluate the Safety and Immunogenicity of CH505M5 N197D mRNA-gp160 Followed by CH505 TF mRNA-gp160 in Adults in Overall Good Health Without HIV

PHASE1RecruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

November 25, 2024

Primary Completion Date

January 3, 2026

Study Completion Date

January 3, 2026

Conditions
HIV Infections
Interventions
BIOLOGICAL

CH505M5 N197D mRNA-gp160

To be administered intramuscularly as a split dose

BIOLOGICAL

CH505 TF mRNA-gp160

To be administered intramuscularly as a split dose

Trial Locations (7)

10032

RECRUITING

Columbia P&S (Site ID: 30329), New York

10065

COMPLETED

New York Blood Center (Site ID: 31801), New York

10400

NOT_YET_RECRUITING

Vaccine Trial Centre, Mahidol University CRS (Site ID: 32021), Bangkok

15213

NOT_YET_RECRUITING

University of Pittsburgh (Site ID: 1001), Pittsburgh

19104

RECRUITING

Penn Prevention (Site ID: 30310), Philadelphia

98104

NOT_YET_RECRUITING

Seattle Vaccine and Prevention (Site ID: 30331), Seattle

02215

NOT_YET_RECRUITING

Beth Israel Deaconess Medical Center (Site ID: 32077), Boston

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

Department of Health and Human Services

FED

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH